论文部分内容阅读
目的:探究分析合并消化系统疾病患者行冠脉支架术后抗凝治疗的疗效。方法:选取近两年在我院接受冠脉支架术后治疗并患有消化疾病患者80例,分为对照组和试验组,每组40人,对照组低分子肝素钙治疗,试验组磺达肝癸钠治疗,观察并比较两组患者的消化道出血、血红蛋白、红细胞计数以及血管的情况。结果:对照组患者术后1个月的消化道出血(32.50%)、血管再血管化(27.50%)明显高于试验组患者术后1个月的消化道出血(5.00%)、血管再血管化(2.50%);对照组术后的血红蛋白(123.21±40.91)g/l、红细胞计数分(4.09±1.25)明显低于试验组术后的血红蛋白(129.04±42.83)g/l、红细胞计数分(4.27±1.36),两组有显著性差异。结论:磺达肝癸钠抗凝治疗冠脉支架术后并患有消化疾病患者中,疗效较好。
Objective: To investigate the efficacy of anticoagulant therapy after coronary stent implantation in patients with digestive system diseases. Methods: Eighty patients with digestive diseases who underwent coronary stenting in our hospital in recent two years were enrolled. They were divided into control group and experimental group, with 40 in each group. The control group was treated with low molecular weight heparin, Hepatic decane sodium treatment, observe and compare the two groups of patients with gastrointestinal bleeding, hemoglobin, red blood cell count and blood vessels. Results: The rate of gastrointestinal bleeding (32.50%) and revascularization (27.50%) in the control group was significantly higher than that of the experimental group (5.00%) at one month after operation, (2.50%). The postoperative hemoglobin (123.21 ± 40.91) g / l and the erythrocyte count (4.09 ± 1.25) in the control group were significantly lower than those of the experimental group (129.04 ± 42.83) g / (4.27 ± 1.36), there was a significant difference between the two groups. Conclusion: Fondaparinux anticoagulant therapy in patients with coronary artery disease and digestive disease, the effect is better.